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S210 Oral Presentationson outcomes. A lower risk of late relapse was seen with several
cGVHD specific variables (P\0.0001), i.e., mild, moderate or severe
cGVHD; de novo or progressive cGVHD; or involvement of any or-
gan with cGVHD. These results demonstrate a protective effect of
cGVHD on late relapse only in CML. In addition, presence of
cGVHD by 1 year after HCT was associated with a higher risk of
TRM and inferior OS in all patients (CML, AML, ALL, MDS).
Since the protective effect of cGVHD on late relapse was seen
only in CML patients, more aggressive measures to control cGVHD
may be beneficial especially in AML, ALL and MDS patients after
high intensity conditioning regimen.20
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Pre-clinical data showed that C3a priming of CD34+ HPC leads
to activation of CXCR4, improved migration towards an SDF1 gra-
dient, and faster hematopoietic recovery and better human engraft-
ment in mice. On the basis of these data, we hypothesized that
preincubation with C3a would be safe and enhance engraftment.
To test this hypothesis, we incubated the smaller of the two UCB
units with C3a 1 mcg/mL (Calbiochem, Gibbstown, NJ) for 30 min-
utes, and infused without washing. Ten patients, median age 62 (r:
30-68), 8 males, with AML (n 5 6), MDS (n 5 3) and Hodgkin’s
(n 5 1) were enrolled. Units were selected using the University of
Minnesota published criteria and all met lot release (endotoxin\5
EU/kg, negative gram stain, viability .45%). Conditioning con-
sisted of cyclophosphamide 50 mg/kg/x1day, fludarabine 40 mg/
m2/x5d, total body irradiation 200cGy/x1dwith antithymocyte glob-
ulin added in three since they had not had recent chemotherapy. Im-
munoprophylaxis consisted of cyclosporine A/mycophenolate
mofetil (MMF). The unmanipulated unit was infused first with the
C3a primed unit infused 30 min later. Patients were monitored for
24 h for evidence of infusional toxicities and activation of pathways
downstream of C3a by assessment of coagulation factors, IL-6,
TNF-alpha, histamine, tryptase and C-reactive protein before and
15, 30 and 60 min post-infusion. Grade 3 hypertension was the
only notable infusional toxicity in 5; no patient had demonstrable ac-
tivation of the complement pathway. Nine patients had neutrophil
recovery at a median of 9 days (range 6-26). On day 21, hematopoi-
esis was primarily derived from the C3a primed unit in 6 of 9 (67%)
evaluable patients and present but non-predominating in another.
While not expected to enhance the speed of neutrophil recovery after
a non myeloablative therapy where initial host recovery in expected,
these data suggest a potential repopulating advantage especially since
the C3a primed unit is smaller and infused last. Based on the safety
profile and potential impact on engraftment, a randomized phase
II clinical trial in the myeloablative setting where neutrophil recov-
ery rates are suboptimal (median 23 days) is being developed.21
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Iron overload is a common complication following hematopoietic
stem cell transplantation (HSCT), and recent evidence suggests that
it has an important influence on both morbidity and mortality. The
C282Y and H63D polymorphisms of the hemochromatosis gene
(HFE) are associated with increased iron absorption. We evaluated119 patients with CML in chronic phase (CML-CP) undergoing
myeloablative HSCT for the presence of HFE polymorphisms.
The frequency of polymorphismswas consistent with that of the nor-
mal population. The presence of the HFE polymorphisms was not
associated with ferritin levels pre or post-transplant and there was
no impact on OS, TRM, or relapse rate. Serum samples were avail-
able for 84 patients at regular intervals post-transplant.We evaluated
serum markers of iron overload and regulation including ferritin,
iron, transferrin saturation (%TSAT), Hepcidin-25, and growth dif-
ferentiation factor-15 (GDF-15) as well as markers of inflammation
such as CRP and interleukin-6 (IL-6).
We found significant associations between Hepcidin-25 levels (\
or.median of 119ng/ml) measured within 3months of HSCT (me-
dian 50.5 days) and 1-year OS (92.9% vs 69%, p5 0.002) and 1-year
TRM (7.6% vs. 29.2% P 5 0.04). The cause of death in all patients
was secondary to infection. There was no impact of Hepcidin-25 on
the occurrence/severity of GVHD (p5 0.64) or the incidence of re-
lapse (p5 0.13). Hepcidin-25 plays a pivotal role in iron metabolism
and its expression can be upregulated by iron overload as well as by
inflammatory stimuli such as IL-6. In keepingwith these findings, in-
creased levels of GDF-15, a member of the TGF-b family and reg-
ulator of Hepcidin-25, were also associated with increased TRM and
inferior 1-year OS (p 5 0.07 and p 5 0.021, respectively). In multi-
variate analysis, Gratwohl score (RR5 13.8, p5 0.001) and Hepci-
din-25 (RR 5 4.2 and p 5 0.027) were the only independent
predictors for 1-year OS. Our results suggest that post-transplant
Hepcidin-25 and GDF-15 levels may be useful biomarkers for pre-
dicting 1-year TRM andOS after HSCT. Larger prospective studies
are warranted to confirm our findings.22
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Background: Acute graft-vs.-host disease (GVHD) remains a major
source of morbidity andmortality after allogeneic hematopoietic cell
transplantation (HCT). CD30 is a cell surface membrane protein of
the tumor necrosis factor receptor family and is expressed on acti-
vated T-cells. We hypothesized that CD30 could be used as a bio-
marker of acute GVHD after allogeneic HCT.
Methods: Peripheral blood mononuclear cells were collected from
12 patients at the time of presentation of symptoms of acute
GVHD, but prior to the initiation of systemic corticosteroids. 15 pa-
tients without GVHD were used as controls (CONTROL). In the
GVHD group, sample collection ranged from day +23 to day +165
after HCT and was based on symptoms or signs suggestive of acute
GVHD. One patient developed GVHD following donor leukocyte
infusion (DLI). In the control group, sample collection ranged
from day +58 to +98 after HCT.
Results:There were no significant differences in baseline character-
istics between the two groups. Analysis by flow cytometry showed
that patients with acuteGVHDhad a higher percentage of CD30 ex-
pressing CD8+ T-cells: median 2.7% (range 0.5%-10.2%) in
GVHD vs. 0.4% (0.2%-3.2%) in CONTROL, (p\0.001). Further
immunophenotypical analysis showed that the difference was quite
pronounced in the effector memory subset (defined by
CD8+,CD45RO+,CD62L-): 3.4% (0.7%, 10.8%) GVHD vs 0.8%
(0.4%, 2.9%)CONTROL, (p5 0.003) and the central memory sub-
set (defined by CD8+,CD45RO+,CD62L+): median 15.6% (2.8%,
25.0%) GVHD vs. 2.3% (1.3%, 10.4%) CONTROL, (p\ 0.001).
There was no significant difference in CD30 expression in na€ıve cells
(CD8+,CD45RO-,CD62L+), CD4+ T-cell subsets, or regulatory
(CD127-,CD25+) T-cells. Time after HCT had no effect on expres-
sion of CD30.
Conclusions:These results suggest that CD30 expression on CD8+
T-cells after allogeneic HCTmay be a potential biomarker for acute
GVHD. More importantly, this study suggests that CD30 may rep-
resent a novel target for the therapy of acute GVHD after HCT.
Analysis with a larger number of samples is ongoing to confirm these
results.
